Summary It has been reported that decreased numbers of dendritic cells (DCs) are correlated with poor prognosis in some types of malignancy, such as gastric cancer. However, factors that determine the density of DCs have not been characterized. It was recently reported that vascular endothelial growth factor (VEGF) inhibits the functional maturation of DCs from CD34-precursors. In this study, we analysed the relationship between the expression of VEGF and the density of DCs in gastric carcinoma tissues by immunohistochemical staining. The extent of infiltration by DCs was graded from marked to slight on the basis of the mean densities of DCs. The prognosis of patients with marked infiltration was significantly better than that of patients with slight infiltration among patients who had undergone curative resection. Multivariate analysis showed that infiltration by DCs was an independent prognostic indicator. Furthermore, there was an inverse correlation between the density of DCs and the expression of VEGF. Our results suggest that expression of VEGF might be associated with tumour progression and poor prognosis not only because VEGF stimulates angiogenesis, but also because it allows tumours to escape from attack by the immune system in patients with gastric carcinoma.
Dendritic cells (DCs) plax an important role in the presentation of tumour antigens and in the induction of specific immune responses to carcinoma. Thus. the infiltration of tumours by DCs is thought to reflect the local immune response ). We reported previously that the survival time of patients with adsvanced gastric cancer w as correlated with the density of DCs that were positive for S-100 protein (Tsujitani et al. 1987 ). Similar results hav-e been obtained by other groups who studied malignancies of the lung (Miyake et al. 1992) . nasopharvnx (Nomori et al. 1986 ). oesophagus (Matsuda et al. 1990 ). large intestine (Ambe et al. 1989 ) and uterine cerv-ix (Nakano et al. 1989 ). However. the mechanism responsible for the control of the densitv of DCs remains unclear.
Vascular endothelial growth factor (VEGF) acts as a mitogen for endothelial cells in *-itro. and it is a potent angiogenesis-promoting factor in viso (Ferrara et al. 1989 : Gospodarow-icz et al. 1989 . It has been isolated from a -ariety of tumorgenic and non-transformed cell lines and is thought to be a major regulator of tumour angiogenesis (Leung et al. 1989) . It was reported recentlI that VEGF produced by human tumours inhibits the functional maturation of DCs from CD4-precursors (Gabrilovich et al. 1996a ). Thus. we postulated that VEGF might influence the density of DCs that express S-100 protein in human gastric adenocarcinoma.
In the current study. both the expression of VEGF and the infiltration by DCs were examined in 140 patients with gastric adenocarcinoma by an immunohistochemical miethod to es aluate the correlation between the expression of VEGF and infiltration by DCs. Tokvo. Japan) and colour image freezer (AE-6905C. ATTO. Tokyo. Japan). DCs were counted in these areas at x200 magnification (x20 objective lens and xlO ocular lens) and their axerage numbers recorded. The visualized area on the displayxwas determined to be 0.075 mm'. Therefore. DCs were counted only in tumour tissues and in gastric mucosa from which penrpheral nernes x-ere absent. Two observers (S.T.. H.S.) did the counting. and the mean value was used for the analysis.
Expression of VEGF
The expression of VEGF wxas detected Awith polyclonal antibodies against VEGF (Santa Cruz BiotechnologN. Santa Cruz. CA. USA: The densitx of DCs correlated w ith prognosis in both stage II and stage III disease but did not correlate in stage I or IV In the previous studv. the density of DCs correlated w-ith prognosis only in stage III. In the current study. we analysed different patients from previous studies and applied a new classification for gastric cancer to our patients (Japanese Research Society for Gastric Cancer. 1995). Thus. the present results might be different from our previous results. Moreover. the prognosis of patients w-ith marked infiltration by DCs was significantly better than that of patients with slight infiltration by DCs in patients ,A ho had undergone curative gastrectomv. Multivariate analx sis showed that the infiltration bv DCs w-as an independent prognostic indicator in the current study.
With regard to the factors that determine the densitv of DCs. no significant correlation w-as found between the density of DCs and pattems of DNA ploidy. w-hich represent the malignant potential of gastric tumours (Kakeji et al. 1993) . The potential for nodal spreading appears to be associated w-ith the g-rowth potential of tumour cells and w-ith the local immune status (Maehara et al. 1997) . The former A as ex aluated on the basis of levels of proliferating cell nuclear antigen (PCNA) and the latter on the basis of infiltration by DCs. The PCNA labelling index and the extent of infiltration bv DCs wxere inxerselx related. These results suggest that decreased infiltration bv DCs might be induced bv cvtokines. (1998) 78(12) . [1573] [1574] [1575] [1576] [1577] both Kdr and Flt 1. w-hich are receptors for VEGF. in CD34-precursors (Katoh et al. 1995) suggests that these cells might be affected by VEGF. Therefore. we investigated whether the expression of VEGF might correlate with the density of S-100 proteinpositiv-e DCs in human gastric adenocarcinoma.
Numerous studies have demonstrated that the expression of VEGF is a significant predictor of an increased risk of metastatic disease. as well as of overall survival by stimulating angiogenesis in gastric carcinoma (Maeda et al. 1996) . oesophageal carcinoma (Inoue et al. 1997 ). breast carcinoma (Toi et al. 1994 ) and non-small-cell lung carcinoma (Fontanini et al. 1997) . We also found that the prognosis of patients whose tumours expressed VEGF was significantly w-orse than that of patients whose tumours did not express VEGF. among, patients who had undergone curative gastrectomy.
In the present study. the expression of VEGF w-as found to be inversely related to the densitv of DCs in gastric carcinoma Moreover. the number of S-100 protein-positive DCs in VEGFne2ative tumours was significantly higher than that in VEGFpositive tumours in patients with gastric carcinoma at stages I. II and 111. Even at stage I'. the number of S-100 protein-positive DCs in VEGF-negative tumours was higher than that in VEGF-positive tumours. but the difference was not significant. Thus. the expression of VEGF might not only be correlated with angiogenesis. which plays an important role in the progression and prognosis of solid tumours. but it might also help tumours to avoid inducing a local immune response. VEGF might play a broader role in the progression of aastric cancer than has previously been considered likelv. Our findings show. for the first time. that the density of S-100 proteinpositive DCs in primary gastric carcinoma might be controlled or influenced by VEGF. On the other hand. no data on immune competence. such as responsiveness to skin antigen testing and recall responses to tetanus toxoid. were recorded in our patients. Further studies are necessarv to clarify the correlation between the expression of VEGF and immunity in patients with gastric carcinoma.
Antiangiogenic agents have received attention in clinical oncolooy as potential therapeutic agrents (O Reilly et al. 1994) . TNP470 is a synthetic analogue of fumagillin with stronc antiangiogenic activity: it inhibits tumour growth and metastasis in experimental models (Yamaoka et al. 1993 : Yanase et al. 1993 . A therapeutic blockade of the action of VEGF might improve prospects for immunotherapy. and it might also inhibit neovascularization of tumours.
In conclusion. expression of VEGF in castric adenocarcinomas was associated with a decrease in the density of S-100 protein-positive DCs. Thus. VEGF might be associated with the progression of tumours and prognosis. not only via angiogenesis but also via avoidance of the induction of an immune response. Therapeutic blockade of the action of VEGF could conceivablv provide a new treatment modality for patients with metastatic tumours.
